Trends›Bio-instruments move onto chips
Bio-instruments move onto chips
Where the measurement transduction step reduces to a lithographically-defined structure on silicon (nanopores, ISFETs, microelectrode arrays, thin-film thermal cyclers, electrochemical and photonic transducers), the instrument built around it industrialises on semiconductor cost and volume curves; by 2030 at least three further laboratory assay categories have…
61 confidence, computed 23 Oct 2026
- Technical
What rests on thismarkets it underwrites or threatens
Evidencethe schedule the figure draws
The evidence, newest first
- Jun 2026
for · Production sequencer built on a reusable CMOS sensor containing millions of nanopores (Genia, acquired 2014) plus SBX chemistry (Stratos Genomics, 2020). Roche launches AXELIOS 1 sequencer on a reusable CMOS nanopore sensor array - Jun 2026
neutral · observable Roche commercially launched AXELIOS 1 on June 29, 2026 for research-use with strategic intent for clinical expansion, with library prep kits and open-source bioinformatics suite. Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform - Jun 2026
for · observable Axelios 1 lists $750k instrument price and $150 per 30X genome cost in duplex mode with reusable sensor module up to 20 times, demonstrating semiconductor cost curve advantages. Roche Sets Sights on Clinic Following Commercial Launch of Axelios 1 Sequencer - May 2026
against · primary Quantum-Si booked $0.5M in Q4 2025 and guides ~$1.0M for FY2026. Chip-native proteomics companies are pre-revenue and slipping - May 2026
against · observable Illumina Q1 2026 sequencing consumables revenue was $726M (+4% YoY), with 80 NovaSeq X placements and clinical consumables growing 20% ex-China, suggesting benchtop incumbent resilience. Illumina Raises 2026 Guidance on Strong Q1 NovaSeqX Demand, Clinical Consumables Sales - Mar 2026
for · observable Baebies' FINDER platform utilizing digital microfluidics cartridge technology received FDA 510(k) clearance and CLIA waiver in March 2026 for multifunctional molecular point-of-care testing. Baebies' Finder Platform Secures Dual FDA Clearance and CLIA Waiver - Feb 2026
for · primary Ultra-fast thermal-cycling PCR, positive result in 6 minutes, from a TTP spin-out founded 2020 in Cambridgeshire; acquired 20 Apr 2026 for roughly $100M, eight weeks after clearance. LEX Diagnostics VELO — FDA 510(k) plus CLIA waiver, acquired by QuidelOrtho ~$100M - Feb 2026
for · observable LEX Diagnostics' cartridge-based VELO system received FDA 510(k) clearance and CLIA waiver approval in February 2026 for PCR-quality respiratory pathogen testing in under 10 minutes. LEX Diagnostics Receives FDA 510(k) Clearance and CLIA Waiver for LEX VELO System - Feb 2026
against · primary Labcorp grew revenue over 7% in 2025 and is building a 500,000 sq ft new central laboratory; Quest grew 13.1%. The central lab is growing, not shrinking - Jan 2026
for · observable CytoChip's CitoCBC system became the first cartridge-based Complete Blood Count (CBC) system to receive FDA CLIA waiver, expanding chip-based testing into hematology. Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer - Jan 2026
for · primary A CMOS-ASIC-based sequencer at real and growing scale twenty years in; clinical adoption up 60%, biopharma up 30%, with headroom to a couple hundred dollars fully-loaded per genome. Oxford Nanopore FY2025 revenue GBP223.9M, +24.2% constant currency - Jan 2026
neutral · claim European Medicines Agency granted CE-IVD marks to 12 new POC cardiac biomarker assays during 2024-2025 but no chip-native platform displacement from benchtop systems specified. Point-of-Care Diagnostics Market Analysis including CE-IVD POC cardiac biomarkers - Dec 2025
for · primary ~10nm pores patterned by EUV across full 300mm wafers with DNA translocation validated at high SNR, plus a 256-channel event-driven readout ASIC at ISSCC 2026. imec demonstrates wafer-scale solid-state nanopores using EUV lithography (IEDM) - Nov 2025
against · primary Leerink analysts stated it will take years of testing to ready Axelios for clinical sequencing with low oncology Dx company adoption expected. Leerink analyst assessment on Roche Axelios clinical sequencing timeline - Jun 2025
against · The 2025 field review states plainly that a complete MEMS mass spectrometer has never been reported. Chip-scale mass spectrometry does not exist commercially (Analytical Chemistry review) - Feb 2025
for · primary 5-part differential, 8-minute turnaround, monthly QC only; Henry Schein signed exclusive distribution Jan 2026. CytoChip CitoCBC — first cartridge-based complete blood count with 510(k) and CLIA waiver - May 2024
against · primary Cue Health $200M IPO 2021 to bankruptcy May 2024 after an FDA warning letter; Lucira bankrupt Feb 2023, sold to Pfizer for $36.4M, shut March 2025; Talis $254M IPO 2021, no longer a public operating company. The point-of-care graveyard — Cue Health, Lucira, Talis
What would move itthe measures watched
- watchCount of FDA CLIA-waiver-by-application decisions for cartridge or chip-based systems, per year. The cleanest count of assay categories actually leaving the central lab. Baseline — CBC first waived Feb 2025, ultra-fast PCR Feb 2026. Two new categories a year sustained means the assumption holds
- watchRoche AXELIOS placements and revenue vs Illumina sequencing-consumables growth. Whether a CMOS-sensor architecture takes real share from an optical incumbent, or the incumbent's installed base and consumable lock-in absorbs it
- watchAnnounced financings at or above EUR10M into merchant bio-transducer / chip-layer suppliers in Europe, per year.